Q-omics provides the consensus-scored PRDX1 profile across patient tissues and cancer cell-line models. PRDX1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, PRDX1 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, PRDX1 RNA expression shows 18,812 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, KICH, and ACC as cancer lineages where PRDX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRDX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRDX1 survival associations across molecular data types. PRDX1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRDX1 RNA expression–survival associations across cancer types. High PRDX1 expression shows unfavorable associations in LIHC, LGG, BLCA, BRCA, ACC and MESO. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for PRDX1 RNA expression.
This table summarizes PRDX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for PRDX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRDX1 shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, BRCA, LIHC and LUSC. The KICH box plot shows higher PRDX1 RNA expression in normal versus tumor tissue (log2 FC = −2.325, t-test p < 0.001).
This table shows molecular features associated with PRDX1 in patient tissues and cancer cell lines. In patient samples, PRDX1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRDX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
